Description: ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.
Home Page: www.valirx.com
VAL Technical Analysis
Stonebridge House
Hatfield,
CM22 7BD
United Kingdom
Phone:
44 2030 084 416
Officers
| Name | Title |
|---|---|
| Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D. | CEO & Director |
| Mr. James Gerry Desler FCA | CFO & Exec. Director |
| Mr. Kumar Nawani | Head of Operations |
| Dr. Catherine Jane Tralau-Stewart Ph.D. | Chief Scientific Officer |
| Mr. Tarquin Edwards | Head of Investor Relations & Communications |
| Mr. Mark Treharne | Corp. Devel. Mang. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9304 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |